Sheena Bhalla

thoracic medical oncology, clinical trials, lung cancer @utswcancer

[Balazs Halmos @BalazsHalmosMD]

I don’t know if they wore Prada or not but double shout-out for 2 fantastic presentations by two legendary and very stylish Women in Thoracic Oncology leaders at #ASCO26 plenary!
#lcsm

[Jonathan Dowell @DrJedDowell]

Great day for the UT Southwestern thoracic medical oncology team (David Gerber, Jill Boudreaux, Alex Lim, @ASridharMD @CynthiaXWei @SheenaBhallaMD ) today at the @LUNGevity HOPE Summit in Dallas! A privilege to interact with the community of lung cancer survivors and caregivers!

[Ben Creelan, MD MS @BenCreelan]

High quality study from @BenjaminBesseMD showing only 26% of pts need retreatment after getting 2 yrs pembro for NSCLC.

However, outcome for IO rechallenge was mixed, w/ many pts clearly not responding and dying. Much like CM-153 & w/ prior pooled report of Abreu-Rodriguez showing only 19-27% ORR with pembro re-challenge.

So still an unresolved question: whether 2-yr discontinuation is optimal for all patients?

@GustaveRoussy

[Sheena Bhalla @SheenaBhallaMD]

@TLCconference continues to be a yearly highlight — thoracic oncology, music, and great colleagues all in one place #TexasLung26 #TinaCascone @StephenVLiu @IASLC @tigirlily

[Sheena Bhalla @SheenaBhallaMD]

Strong turnout this morning at the @GO2forLungCancr Dallas 5K in support of lung cancer care and research! #lcsm @utswcancer @DrJedDowell @ASridharMD

[Arthi Sridhar @ASridharMD]

Exciting ! Come join us in Dallas for the 2026 HOPE Summit! A great opportunity for patients, and families to connect with each other and their care teams!
@utswcancer @utswcancer @SheenaBhallaMD @DrJedDowell @lungoncdoc @drshieldsmd

[Sheena Bhalla @SheenaBhallaMD]

Grateful to work alongside such a strong, talented, and compassionate team #LungCancerAwarenessMonth @utswcancer @DrJedDowell @SawsanRashdanMD @ASridharMD @MVonitzstein @kenwestover

[UTSW Simmons Cancer Center @utswcancer]

Our teams stand together in the fight against lung cancer – advancing awareness of prevention, early detection, timely treatment, and groundbreaking research.
#LungCancerAwarenessMonth

[Fumiko Ladd Chino, MD, FASCO @fumikochino]

A patient came to the clinic with her unused medication and said "Can you do something with this? THIS is a Honda Civic".

#ASCOQLTY25 @ASCO Dr Emily R. Mackler, PharmD on the benefits of the @YesRxMichigan program. It helps patients, save MILLIONS of dollars, and reduces waste.

[Eric K. Singhi, MD @lungoncdoc]

FOUND: my lung cancer research friends here at #ASCOQLTY25 🤍

@LUNGevity @SheenaBhallaMD @ASCO

[Stephen V Liu, MD @StephenVLiu]

Report @JTOonline on DLL3 expression in #EGFR NSCLC after #SCLC transformation. DLL3 positive in 11/12 patients. Two of these patients received tarlatamab (one with osimertinib) with clinical benefit. Need prospective data here!

https://t.co/FmnOO32AYR

[UTSW Simmons Cancer Center @utswcancer]

Register now for our 2025 Oncology Year in Review CME! https://t.co/NBmzlK6sj7

This program will provide participants with the latest information available as presented at the @ASCO meeting, @myESMO meeting, and other meetings that took place in 2025 from @UTSWMedCenter experts.

[Sheena Bhalla @SheenaBhallaMD]

Kudos to David Gerber and the E4512 team for their efforts towards improving outcomes in early-stage NSCLC. Even negative studies move the field forward.
#WCLC25 #LCSM @IASLC @utswcancer @UTSWHemeOnc

[Patrick Forde @FordePatrick]

Finally at #wclc25 plenary labor of love phase 3 trial led by Dr. David Gerber, no benefit from adj crizotinib in resected ALK pos lung cancer. Somewhat surprising but important results, despite lower cost crizotinib cannot be substituted effectively for adjuvant alectinib #LCSM

[Laura Alder, MD @LauraAlderMD]

So grateful to be part of this amazing opportunity @IASLC #IASLCAcademy, truly outstanding mentors and co-mentees; so exciting and inspiring to see the research being done in #LCSM at #wclc2025! Looking forward to continuing the collaborations and new friendships!

[UTSW Radiation Oncology @UTSW_RadOnc]

Meet Callie, a certified therapy dog who brings comfort, joy, and plenty of outfits to patients and staff in our department, across UT Southwestern, and throughout the Dallas-Fort Worth area! #NationalDogDay

📖🐕‍🦺: https://t.co/f0vDLhx6yp

[Sheena Bhalla @SheenaBhallaMD]

Thanks to @binaytara for the opportunity to visit El Paso and discuss key updates from #ASCO2025 with my @UTSWHemeOnc colleagues — @ASridharMD @BenDrapkin @TimothyJBrownMD @utswcancer

[Eric K. Singhi, MD @lungoncdoc]

Lung & Order starts NOW 👩‍⚖️— The trial of the century: Frontline treatment for EGFR positive mNSCLC

#TexasLung25 @TLCconference

[Jennifer A. Marks, MD @jennifermarksmd]

Immunotherapy session this morning 🔥
#TexasLung25 @SheenaBhallaMD @HosseinBorghaei @JulieBrahmer @LudaBazhenovaMD @FSkoulidis @ShirishGadgeel @jeffyoriomd

[QianJanieQin @QianJanieQin]

What a line up discussing new&exciting therapies in #lung cancer with highlights in the perioperarive space, utility of #osimertinib #rybervant for #EGFR patients, and #ADC for #mNSCLC with @SheenaBhallaMD @SawsanRashdanMD Dr. David Gerber @TiansterZhang @OncLive @utswcancer

[Sheena Bhalla @SheenaBhallaMD]

Educational morning learning from my GU oncology colleagues! @TiansterZhang @QianJanieQin @PGrivasMDPhD #OncLiveSOSS @utswcancer @UTSWHemeOnc

[Sheena Bhalla @SheenaBhallaMD]

Excellent overview of recent perioperative strategies in kidney cancer from @QianJanieQin #OncLiveSOSS @utswcancer @UTSWHemeOnc

[Petros Grivas @PGrivasMDPhD]

Congrats @QianJanieQin for a wonderful talk on peri-op Tx in RCC! Adjuvant pembro prolonged OS, other adjuvant trials did not meet primary endpoint. Neoadjuvant Tx still experimental. Need for biomarkers! @OncLiveSOSS @TiansterZhang @TDorffOnc @HHammersMD @SuzanneColeMD @Uromigos